A PHASE 1, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VONOPRAZAN- OR ESOMEPRAZOLE-BASED BISMUTH-CONTAINING QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION IN CHINA
Jia Miao 1
Chao Hu
Jie Tang
Wenyan Wang 2
Ying Wang
Ruoting Men
Li Yang
Liqun Gu 3
Naoki Yoshida 4
Richard Czerniak 5
1 West China Hospital, Sichuan University, Chengdu, China
2 ICU, West China Hospital, Sichuan University, Chengdu, China
3 Takeda Development Center Asia, Shanghai, China
4 Takeda Development Center Japan, Osaka, Japan
5 Takeda Pharmaceuticals International Co, Massachusetts, United States
Session
H. pylori (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]